Huaren Pharmaceutical Co., Ltd. (300110.SZ)
CNY 2.9
(3.2%)
CNY 2.9
(3.2%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 431.65 Million CNY | -5.56% |
| 2022 | 419.6 Million CNY | 6.14% |
| 2021 | 348.33 Million CNY | 49.53% |
| 2020 | 236.04 Million CNY | 5.47% |
| 2019 | 206.1 Million CNY | 23.51% |
| 2018 | 196.82 Million CNY | -7.83% |
| 2017 | 261.18 Million CNY | 14.87% |
| 2016 | 236.59 Million CNY | -2.91% |
| 2015 | 197.77 Million CNY | 4.28% |
| 2014 | 200.64 Million CNY | -20.71% |
| 2013 | 252.71 Million CNY | 53.33% |
| 2012 | 160.02 Million CNY | 21.25% |
| 2011 | 138.78 Million CNY | 3.24% |
| 2010 | 123.52 Million CNY | 23.33% |
| 2009 | 96 Million CNY | 42.88% |
| 2008 | 77.4 Million CNY | 18.48% |
| 2007 | 53.2 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 38.45 Million CNY | -49.88% |
| 2024 Q3 | 40.42 Million CNY | -3.1% |
| 2024 Q1 | 83.24 Million CNY | -4.78% |
| 2023 Q3 | 93.3 Million CNY | 25.03% |
| 2023 Q4 | 72.31 Million CNY | -22.5% |
| 2023 FY | - CNY | -5.56% |
| 2023 Q1 | 69.31 Million CNY | -29.32% |
| 2023 Q2 | 74.62 Million CNY | 7.66% |
| 2022 FY | - CNY | 6.14% |
| 2022 Q2 | 80.29 Million CNY | 37.5% |
| 2022 Q3 | 75.76 Million CNY | -5.64% |
| 2022 Q4 | 98.07 Million CNY | 29.44% |
| 2022 Q1 | 58.39 Million CNY | -33.34% |
| 2021 Q3 | 78.45 Million CNY | -3.55% |
| 2021 FY | - CNY | 49.53% |
| 2021 Q1 | 53.03 Million CNY | -40.94% |
| 2021 Q2 | 81.33 Million CNY | 53.37% |
| 2021 Q4 | 87.6 Million CNY | 11.67% |
| 2020 FY | - CNY | 5.47% |
| 2020 Q3 | 27.84 Million CNY | -42.57% |
| 2020 Q4 | 89.79 Million CNY | 222.43% |
| 2020 Q1 | 11.57 Million CNY | -85.02% |
| 2020 Q2 | 48.49 Million CNY | 319.01% |
| 2019 Q3 | 24.05 Million CNY | -41.08% |
| 2019 FY | - CNY | 23.51% |
| 2019 Q1 | 17.51 Million CNY | -62.5% |
| 2019 Q2 | 40.83 Million CNY | 133.14% |
| 2019 Q4 | 77.26 Million CNY | 221.15% |
| 2018 Q1 | 28.31 Million CNY | 267.85% |
| 2018 FY | - CNY | -7.83% |
| 2018 Q4 | 46.7 Million CNY | 156.51% |
| 2018 Q2 | 13.92 Million CNY | -50.81% |
| 2018 Q3 | 18.2 Million CNY | 30.74% |
| 2017 Q3 | 64.33 Million CNY | 293.94% |
| 2017 Q4 | 7.69 Million CNY | -88.03% |
| 2017 FY | - CNY | 14.87% |
| 2017 Q2 | 16.32 Million CNY | -22.48% |
| 2017 Q1 | 21.06 Million CNY | -37.65% |
| 2016 Q4 | 33.78 Million CNY | 50.8% |
| 2016 Q1 | 18.68 Million CNY | 241.84% |
| 2016 Q2 | 10.38 Million CNY | -44.42% |
| 2016 Q3 | 22.4 Million CNY | 115.69% |
| 2016 FY | - CNY | -2.91% |
| 2015 FY | - CNY | 4.28% |
| 2015 Q2 | 27.82 Million CNY | -14.97% |
| 2015 Q3 | 31.19 Million CNY | 12.12% |
| 2015 Q4 | 5.46 Million CNY | -82.47% |
| 2015 Q1 | 32.71 Million CNY | 257.27% |
| 2014 Q3 | 44.01 Million CNY | 202.02% |
| 2014 Q4 | 9.15 Million CNY | -79.19% |
| 2014 Q1 | 41.79 Million CNY | -30.96% |
| 2014 Q2 | 14.57 Million CNY | -65.13% |
| 2014 FY | - CNY | -20.71% |
| 2013 Q3 | 43.93 Million CNY | 28.15% |
| 2013 Q1 | 37.53 Million CNY | -7.12% |
| 2013 Q4 | 60.53 Million CNY | 37.8% |
| 2013 FY | - CNY | 53.33% |
| 2013 Q2 | 34.28 Million CNY | -8.67% |
| 2012 Q2 | 31.22 Million CNY | 36.21% |
| 2012 Q4 | 40.41 Million CNY | 16.9% |
| 2012 Q1 | 22.92 Million CNY | -45.81% |
| 2012 FY | - CNY | 21.25% |
| 2012 Q3 | 34.57 Million CNY | 10.73% |
| 2011 FY | - CNY | 3.24% |
| 2011 Q3 | 22.43 Million CNY | -12.86% |
| 2011 Q2 | 25.74 Million CNY | 21.13% |
| 2011 Q4 | 42.29 Million CNY | 88.53% |
| 2011 Q1 | 21.25 Million CNY | -33.29% |
| 2010 FY | - CNY | 23.33% |
| 2010 Q1 | 21.2 Million CNY | -5.39% |
| 2010 Q2 | 29.59 Million CNY | 39.58% |
| 2010 Q3 | 22.24 Million CNY | -24.84% |
| 2010 Q4 | 31.86 Million CNY | 43.26% |
| 2009 Q3 | 29.54 Million CNY | 0.0% |
| 2009 Q4 | 22.4 Million CNY | -24.16% |
| 2009 FY | - CNY | 42.88% |
| 2008 FY | - CNY | 18.48% |
| 2007 FY | - CNY | 0.0% |